Literature DB >> 20570692

Olanzapine causes hypothermia, inactivity, a deranged feeding pattern and weight gain in female Wistar rats.

S S Evers1, F Calcagnoli, G van Dijk, A J W Scheurink.   

Abstract

Olanzapine is an a-typical antipsychotic drug antagonizing predominantly 5-HT and dopamine, but also histamine, muscarin, and α-adrenergic receptors. In humans, Olanzapine induces weight gain and increases the risk of type 2 diabetes. The underlying mechanisms of Olanzapine-induced weight gain are unclear. To study this we administered Olanzapine (5mg/kg) in female Wistar rats on a medium fat diet for 14 days via a permanent gastric catheter twice a day, just prior to the onset and at the middle of dark phase. Food and water intake, locomotor activity and body temperature were measured. Olanzapine acutely induced hypothermia, markedly decreased locomotor activity and increased body weight during 14 days of treatment. Olanzapine treatment did not result in an alteration of 24h food intake, but diurnal patterns of feeding behavior and body temperature were dramatically changed. We conclude that in female Wistar rats Olanzapine has an acute hypothermic effect, that the effect of Olanzapine on feeding behavior is secondary to the effect on activity, and that Olanzapine-induced weight gain is primarily the result of reduction in locomotor activity.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20570692     DOI: 10.1016/j.pbb.2010.05.029

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  6 in total

1.  Chronic treatment with olanzapine increases adiposity by changing fuel substrate and causes desensitization of the acute metabolic side effects.

Authors:  Elodie M Girault; Bruno Guigas; Anneke Alkemade; Ewout Foppen; Mariëtte T Ackermans; Susanne E la Fleur; Eric Fliers; Andries Kalsbeek
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-11-05       Impact factor: 3.000

2.  Residual dopamine receptor desensitization following either high- or low-dose sub-chronic prior exposure to the atypical anti-psychotic drug olanzapine.

Authors:  Flávia Regina Cruz Dias; Liana Wermelinger de Matos; Maria de Fátima Dos Santos Sampaio; Robert J Carey; Marinete Pinheiro Carrera
Journal:  Psychopharmacology (Berl)       Date:  2012-07-24       Impact factor: 4.530

Review 3.  Atypical antipsychotics and effects on feeding: from mice to men.

Authors:  Louise Benarroch; Chantel Kowalchuk; Virginia Wilson; Celine Teo; Melanie Guenette; Araba Chintoh; Yasika Nesarajah; Valerie Taylor; Peter Selby; Paul Fletcher; Gary J Remington; Margaret K Hahn
Journal:  Psychopharmacology (Berl)       Date:  2016-06-01       Impact factor: 4.530

4.  Olanzapine Administration Reduces Chemotherapy-Induced Nausea Behavior in Rats.

Authors:  Rosario B Jaime-Lara; Tito Borner; Ruby A Holland; Evan Shaulson; Brianna Brooks; Bart C De Jonghe
Journal:  Biol Res Nurs       Date:  2021-04-01       Impact factor: 2.318

5.  Influence of olanzapine on serum prolactin levels and BMI in female patients with schizophrenia.

Authors:  Fuyin Yang; Lan Chen; Xinyu Fang; Ke Zheng; Cheng Zhu; Chaoqun Xu; Chen Zhang; Wei Tang
Journal:  Neuropsychiatr Dis Treat       Date:  2018-12-13       Impact factor: 2.570

6.  Olanzapine-Induced Therapeutic Hypothermia Attenuates Renal Injury in Rats after Asphyxial Cardiac Arrest and Resuscitation.

Authors:  Tsendsuren Tungalag; Yeo-Jin Yoo; Hyun-Jin Tae; Dong Kwon Yang
Journal:  Antioxidants (Basel)       Date:  2022-02-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.